Perrigo’s Loratadine 505(b)(2) NDA Was Properly Submitted, Firm Maintains
This article was originally published in The Tan Sheet
Executive Summary
Perrigo chose to file a 505(b)(2) NDA for its generic loratadine 10 mg tablet because at the time it submitted the application, reference listed drug Claritin still was a prescription product, the firm states in recent comments to FDA
You may also be interested in...
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team